Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

New England Journal of Medicine

Volumn 349, Issue 15, 2003, Pages 1423-1432

  Hughes, Tim P ^a   Kaeda, Jaspal ^b   Branford, Susan ^a   Rudzki, Zbigniew ^a   Hochhaus, Andreas ^c   Hensley, Martee L ^d   Gathmann, Insa ^d   Bolton, Ann E ^d   Van Hoomissen, Iris C ^d   Goldman, John M ^b   Radich, Jerald P ^e  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; GENE PRODUCT; IMATINIB;

ADULT; AGED; ARTICLE; BCR ABL GENE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUSION GENE; GENE CONTROL; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ACTUARIAL ANALYSIS; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 10744229080     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa030513     Document Type: Article

References (40)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
2. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824-30.
4. Chronic Myeloid Leukaemia Trialists' Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukaemia: a meta-analysis of seven randomised trials. J Natl Cancer Inst 1997;89:1616-20.
5. Guilhot F, Chastang C, Michallet M, et al. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337: 223-9.
6. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukaemia. Blood 2002;99:1527-35.
7. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074-81.
8. Mahon F, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon-α. J Clin Oncol 2002;20:214-20.
9. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993;82:1929-36.
10. Lion T, Gaiger A, Henn T, et al. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 1995;9:1353-60.
11. Hochhaus A, Lin F, Reiter A, et al. Quantification of residual disease in chronic myeloid leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood 1996;87:1549-55.
12. Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999;13: 1825-32.
13. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999;107;587-99.
14. Preudhomme C, Revillion F, Merlat A, et al. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 1999;13:957-64.
15. Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 2001;98:1701-7.
16. van Rhee F, Marks DI, Lin F, et al. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia 1995;9:329-35.
17. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 1998;16: 1526-31.
18. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 2000;95:62-6.
19. Buchdunger E, Zimmerman J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56:100-4.
20. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
21. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
22. Goldman JM, Druker BJ. Chronic myeloid leukaemia: current treatment options. Blood 2001;98:2039-42.
23. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with chronic myelogenous leukemia and myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
24. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukaemia: results of a phase 2 study. Blood 2002;99: 1928-37.
25. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52. [Erratum, N Engl J Med 2002;346;1923.]
26. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
27. Mughal TI, Yong A, Szydlo RM, et al. Molecular studies in patients wtih chronic myelogenous leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001;115:569-74.
28. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25: 49-61.
29. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myelogenous leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850-8.
30. Morley A. Quantifying leukemia. N Engl J Med 1998;339:627-9.
31. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of the polymerase chain reaction in predicting relapse. Blood 1991; 77:874-8.
32. Roth MS, Antin JH, Ash R, et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992;79:276-82.
33. Lin F, van Rhee F, Goldman JM, Cross NCP. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996;87:4473-8.
34. Mackinnon S, Barnett L, Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation of chronic myeloid leukemia. Bone Marrow Transplant 1996;17:643-7.
35. Miyamura K, Tahara T, Tanimoto M, et al. Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. Blood 1993;81:1089-93.
36. Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001;97: 1560-5.
37. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101:97-100.
38. Hughes TP, Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol 2003;40:Suppl 3:62-8.
39. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118:771-7.
40. Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002;16:1579-83.